Neoadjuvant androgen deprivation therapy with or without Fc-enhanced non-fucosylated anti-CTLA-4 (BMS-986218) in high risk localized prostate cancer: a randomized phase 1 trial.
Ager CR, Obradovic A, McCann P, Chaimowitz M, Wang ALE, Shaikh N, Shah P, Pan S, Laplaca CJ, Virk RK, Hill JC, Jugler C, DeFranco G, Bhattacharya N, Scher HI, DeCastro GJ, Anderson CB, McKiernan JM, Spina CS, Stein MN, Runcie K, Drake CG, Califano A, Dallos MC.
Ager CR, et al. Among authors: bhattacharya n.
medRxiv [Preprint]. 2024 Sep 11:2024.09.09.24313308. doi: 10.1101/2024.09.09.24313308.
medRxiv. 2024.
PMID: 39314954
Free PMC article.
Preprint.